Form 8-K

8-K — Century Therapeutics, Inc.

Accession: 0001104659-26-059824

Filed: 2026-05-13

Period: 2026-05-13

CIK: 0001850119

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — tm2614312d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2614312d1_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2614312d1_8k.htm · Sequence: 1

false

0001850119

2026-05-13

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

May 13, 2026

Century Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-40498

84-2040295

(State or other jurisdiction of

incorporation or organization)

(Commission File Number)

(I.R.S. Employer

Identification No.)

North 38th Street, 11th Floor

Philadelphia, Pennsylvania

19104

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: (267) 817-5790

Not Applicable

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.

below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name

of Exchange on Which Registered

Common Stock, par value $0.0001 per share

IPSC

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ¨

Item 2.02

Results of Operations and Financial Condition

On May 13, 2026, Century Therapeutics, Inc. (the “Company”)

issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished

as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Item 2.02 (including Exhibit 99.1)

is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,

as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated

by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by

specific reference in such filing.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

Exhibit

No.

Document

99.1

Press Release of Century

Therapeutics, Inc., dated May 13, 2026

104

Cover Page Interactive

Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CENTURY THERAPEUTICS, INC.

By:

/s/ Brent Pfeiffenberger, Pharm.D.

Name:

Brent Pfeiffenberger, Pharm.D.

Title:

President and Chief Executive Officer

Date: May 13, 2026

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2614312d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Century Therapeutics Reports First Quarter Financial Results

and Business Updates

· CNTY-813, Century’s type 1 diabetes iPSC-derived islet therapy

with functional-cure potential, remains on track for IND in 4Q 2026; initial

clinical data expected in 2H 2027

· Upcoming oral presentation at the American Diabetes Association (ADA) annual Scientific Sessions highlighting CNTY-813

preclinical data on June 8, 2026

· On track to advance CNTY-308, Century’s CD19-targeted

CAR-iT cell therapy, into the clinic this year

· Cash runway into 1Q 2029 with cash, cash equivalents, and marketable securities of $217.0 million as of March 31, 2026

PHILADELPHIA, May 13,

2026 -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced

pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today reported financial

results for the first quarter ended March 31, 2026, and recent business highlights.

“We

are executing our pipeline with discipline to deliver an iPSC-derived islet replacement therapy to patients. The progress of CNTY-813

highlights what Century can achieve pairing our Allo-Evasion™ engineering

with a scalable iPSC platform,” said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics. “In

a relatively short time since initiating this program, we have advanced CNTY-813

into IND-enabling studies on a timeline we believe is highly competitive

with leading efforts in the field. With an IND submission expected in the fourth quarter of 2026 and initial clinical data anticipated

in the second half of 2027, our focus is clear: to deliver a differentiated, patient-centric,

potentially curative approach for people with type 1 diabetes while continuing to expand our autoimmune disease portfolio with CNTY-308.”

First Quarter 2026 and Recent Highlights

Pipeline

· CNTY-813, Century’s priority program in type 1 diabetes,

reflects strong execution: During Q1 2026, the company made meaningful progress across key IND-enabling

activities, including non-clinical development, manufacturing, and regulatory

readiness, supporting a clear line of sight to the clinic. Progress to date includes compelling preclinical data showing durable glucose

control and immune protection, completion of GMP Master Cell Bank manufacturing, and recent FDA engagement, further de-risking

the program. Building on this momentum, Century expects to submit an IND in 4Q 2026,

subject to completion of remaining studies, and anticipates initial clinical data in the second half of 2027.

· Upcoming ADA presentation highlights Century’s islet cell replacement therapy engineered with Allo-Evasion™ 5.0: Century

will deliver an oral presentation at the ADA 86th Scientific Sessions titled “CNTY-813:

Scalable Production of Allo-Evasion™ 5.0-Engineered

iPSC Beta Islets for Off-the-Shelf

Cell Therapies” (Oral Presentation 1318-OR; Monday, June 8, 2026),

highlighting scalable production of iPSC-derived islets with robust endocrine function and the demonstrated ability to evade the host

immune system.

· CNTY-308 to progress through IND-enabling studies with clinical

trial planned to initiate in 2026: Century remains on track to complete IND-enabling

activities for CNTY-308 and initiate clinical testing in 2026, pending

regulatory clearance. CNTY-308 is a CD19-targeted

CD4⁺/CD8⁺

αβ CAR-iT cell therapy engineered with Allo-Evasion™

5.0 for B-cell-mediated

diseases. Previously presented preclinical data showed functional comparability to primary CAR-T

cells, including target-driven proliferation, cytokine secretion, and

durable persistence. Collectively, these results and the expanding clinical validation of CAR-T

therapy support Century’s confidence that CNTY-308 could deliver

autologous-like benefits in an allogeneic, patient-centric

format designed to broaden access.

Corporate

· As previously disclosed,

completed oversubscribed $135 million private placement financing in January 2026

(HERE for more details).

First Quarter 2026 Financial Results

· Cash Position: Cash, cash equivalents, and marketable securities were $217.0 million as of March 31, 2026, as

compared to $117.1 million as of December 31, 2025. Net cash used in operations was $25.3 million for the quarter ended March 31,

2026, compared to net cash used in operations of $34.6 million for the quarter ended March 31, 2025. The company estimates its cash,

cash equivalents, and investments as of March 31, 2026 will support operations into the first quarter of 2029.

· Research and Development (R&D) Expenses: R&D expenses were $17.1 million for the quarter ended March 31,

2026, compared to $26.6 million for the same period in 2025. The decrease was primarily the result of a reduction in personnel and lower

clinical trial spending.

· General and Administrative (G&A) Expenses: G&A expenses were $6.6 million for quarter ended March 31,

2026, compared to $8.4 million for the same period in 2025.

· Net Income (Loss): Net (loss) was $21.6 million for the quarter ended March 31, 2026, compared to net income of $76.6 million

for the same period in 2025.

About Century Therapeutics

Century

Therapeutics (NASDAQ: IPSC) is a biotechnology company advancing a pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies

with the potential to meaningfully address autoimmune diseases, including type 1 diabetes, and cancer. The company’s therapies

are derived from its iPSC cell foundry and leverage its novel immune evasion engineering technology, Allo-Evasion™. Century

believes its approach to developing off-the-shelf cell therapies will expand patient access and provide advantages over existing cell

therapies which will ultimately advance the course of care. For more information on Century Therapeutics, please visit www.centurytx.com and

connect with us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning

of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained

in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including

but not limited to, statements our timing and expectations regarding our preclinical and clinical development programs, including their

planned development, therapeutic potential and market opportunity, ongoing and planned regulatory submissions and interactions, the achievement

of developmental milestones, corporate strategies, anticipated data readouts, and our financial resources and expected cash runway are

forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause

our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed

or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,”

“might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,”

“anticipate,” “could,” “intend,” “target,” “project,” “contemplate,”

“believe,” “estimate,” “predict,” “forecast,” “potential” or “continue”

or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions.

We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends

that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as

of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted

or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future

product candidates through development activities, preclinical studies, and clinical trials; our ability to meet development milestones

on anticipated timelines; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials,

which may not be predictive of final results or the results of later-stage clinical trials; our ability to obtain clearance of our future

IND or CTA submissions and commence and complete clinical trials on expected timelines, or at all; our reliance on the maintenance of

certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood

of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of geopolitical issues,

trade disputes and tariffs, banking instability and inflation on our business and operations, supply chain and labor force; the performance

of third parties in connection with the development of our product candidates, including third parties conducting our clinical trials

as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales

and marketing capabilities, if our product candidates are approved; our ability to recruit and maintain key members of management and

our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are

described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission

and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and

circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from

those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties

may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except

as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as

a result of any new information, future events, changed circumstances or otherwise.

For More Information:

Century Therapeutics

Douglas Carr

Senior Vice President, Finance

investor.relations@centurytx.com

Corey Davis, Ph.D.

LifeSci Advisors, LLC

212-915-2577

cdavis@lifesciadvisors.com

Century Therapeutics, Inc

Condensed Balance Sheets

(unaudited, in thousands)

March 31,

December 31,

Assets

2026

2025

Current Assets:

Cash and cash equivalents

$ 51,048

$ 61,853

Short-term investments

83,755

55,261

Prepaid expenses and other current assets

4,236

3,655

Total current assets

139,039

120,769

Property and equipment, net

47,606

50,026

Operating lease right-of-use assets

20,972

16,139

Long-term investments

82,169

Intangible assets

34,200

Other long-term assets

2,567

2,570

Total assets

$ 326,553

$ 223,704

Liabilities, convertible preferred stock, and stockholders' equity

Current liabilities:

Accounts payable

$ 3,150

$ 4,773

Accrued expenses and other liabilities

8,477

11,696

Contingent consideration liability, short term

1,939

3,757

Total current liabilities

13,566

20,226

Operating lease liability, long-term

43,942

40,241

Deferred tax liability

4,301

Total liabilities

61,809

64,768

Stockholders' equity

Common stock

Additional paid-in capital

1,078,873

950,814

Accumulated deficit

(813,562 )

(791,917 )

Accumulated other comprehensive income

(585 )

Total stockholders' equity

264,744

158,936

Total liabilities and stockholders' equity

$ 326,553

$ 223,704

Century Therapeutics, Inc

Condensed consolidated statements of operations

(unaudited, in thousands, except share and per share amounts)

Three Months Ended

March 31, 2026

March 31, 2025

Collaboration Revenue

$ -

$ 109,164

Operating Expenses

Research and development

17,105

26,580

General and administrative

6,579

8,408

Total operating expenses

23,684

34,988

Income (loss) from operations

(23,684 )

74,176

Interest income

2,019

2,422

Other income (loss)

(38 )

Total other income

2,039

2,384

Net income (loss)

$ (21,645 )

$ 76,560

Unrealized loss on investments

(615 )

(19 )

Comprehensive income (loss)

$ (22,260 )

$ 76,541

Net income (loss) per common share

Basic and Diluted

(0.11 )

0.89

Weighted average common shares outstanding

Basic

193,474,913

86,021,188

Weighted average common shares outstanding

Diluted

193,474,913

86,098,619

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

May 13, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 13, 2026

Entity File Number

001-40498

Entity Registrant Name

Century Therapeutics, Inc.

Entity Central Index Key

0001850119

Entity Tax Identification Number

84-2040295

Entity Incorporation, State or Country Code

Entity Address, Address Line One

North 38th Street

Entity Address, Address Line Two

11th Floor

Entity Address, City or Town

Philadelphia

Entity Address, State or Province

Entity Address, Postal Zip Code

19104

City Area Code

267

Local Phone Number

817-5790

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

IPSC

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration